[go: up one dir, main page]

NO20013861L - Stabile, vannfrie, visköse enkeltfaseb¶rere og formuleringer hvor slike benyttes - Google Patents

Stabile, vannfrie, visköse enkeltfaseb¶rere og formuleringer hvor slike benyttes

Info

Publication number
NO20013861L
NO20013861L NO20013861A NO20013861A NO20013861L NO 20013861 L NO20013861 L NO 20013861L NO 20013861 A NO20013861 A NO 20013861A NO 20013861 A NO20013861 A NO 20013861A NO 20013861 L NO20013861 L NO 20013861L
Authority
NO
Norway
Prior art keywords
formulations
anhydrous
stable
phase carriers
carriers
Prior art date
Application number
NO20013861A
Other languages
English (en)
Other versions
NO20013861D0 (no
Inventor
Stephen A Berry
Pamela J Fereira
Houdin Dehnad
Anna Muchnik
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22382917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20013861(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20013861D0 publication Critical patent/NO20013861D0/no
Publication of NO20013861L publication Critical patent/NO20013861L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Oppfinnelsen angår stabile, vannfrie, viskøse enkeltfase-bærere og formuler-inger hvor slike bærere benyttes. For-muleringene omfatter minst ett aktivt middel jevnt suspendert i bæreren. Formuleringen kan lagres ved temperaturer fra kaldt til kroppstemperatur i'lengre tidsperioder. Formuleringen kan avgis jevnt fra medikamentavleveringssystemer med en skjærhastighet ved utløpet på fra 1 s"til Is".
NO20013861A 1999-02-08 2001-08-08 Stabile, vannfrie, visköse enkeltfaseb¶rere og formuleringer hvor slike benyttes NO20013861L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11917099P 1999-02-08 1999-02-08
PCT/US2000/002772 WO2000045790A2 (en) 1999-02-08 2000-02-02 Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

Publications (2)

Publication Number Publication Date
NO20013861D0 NO20013861D0 (no) 2001-08-08
NO20013861L true NO20013861L (no) 2001-09-20

Family

ID=22382917

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013861A NO20013861L (no) 1999-02-08 2001-08-08 Stabile, vannfrie, visköse enkeltfaseb¶rere og formuleringer hvor slike benyttes

Country Status (22)

Country Link
EP (2) EP1152749B1 (no)
JP (1) JP4861551B2 (no)
KR (2) KR20080045300A (no)
CN (1) CN1232244C (no)
AR (1) AR029613A1 (no)
AT (2) ATE322889T1 (no)
AU (1) AU775904B2 (no)
CA (1) CA2361424C (no)
CO (1) CO5140096A1 (no)
CY (1) CY1119950T1 (no)
DE (1) DE60027272T2 (no)
DK (1) DK1666026T4 (no)
ES (2) ES2379471T5 (no)
HK (1) HK1041451B (no)
HU (1) HUP0200202A3 (no)
IL (1) IL144755A0 (no)
NO (1) NO20013861L (no)
NZ (1) NZ513441A (no)
PT (2) PT1152749E (no)
TW (2) TW200730199A (no)
WO (1) WO2000045790A2 (no)
ZA (1) ZA200106443B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931282B2 (ja) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
RU2342118C2 (ru) * 2002-12-19 2008-12-27 Алза Корпорейшн Стабильные неводные однофазные гели и композиции на их основе для доставки из имплантируемого устройства
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050008661A1 (en) 2003-03-31 2005-01-13 Fereira Pamela J. Non-aqueous single phase vehicles and formulations utilizing such vehicles
EP1613389B8 (en) 2003-03-31 2008-05-07 Intarcia Therapeutics, Inc. Osmotic pump with means for dissipating internal pressure
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1877077A2 (en) 2005-02-03 2008-01-16 Intarcia Therapeutics, Inc. An implantable interferon-containing device
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
MX2009001114A (es) 2006-08-09 2009-02-10 Intarcia Therapeutics Inc Sistemas de suministro osmotico y ensambles de piston.
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
DK2462246T3 (da) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
BR112012023421B1 (pt) 2010-03-17 2021-09-14 Novaliq Gmbh Composição farmacêutica para tratamento de aumento de pressão intraocular
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2714008B1 (en) 2011-05-25 2016-12-14 Novaliq GmbH Pharmaceutical composition for administration to nails
PL2714010T3 (pl) 2011-05-25 2017-08-31 Novaliq Gmbh Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach
SG11201401360XA (en) 2011-10-25 2014-05-29 Onclave Therapeutics Ltd Antibody formulations and methods
AU2013211645B2 (en) 2012-01-23 2017-06-15 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
CA2997744C (en) 2012-09-12 2019-12-31 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
CA3142049C (en) 2012-09-12 2023-08-29 Novaliq Gmbh Semifluorinated alkane compositions
CA2918419C (en) 2013-07-23 2022-05-03 Novaliq Gmbh Stabilized antibody compositions
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
DK3356313T3 (da) 2015-09-30 2020-07-20 Novaliq Gmbh 2-perfluorhexyloktan til oftalmisk indgivelse
WO2017055454A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP2019520357A (ja) 2016-06-23 2019-07-18 ノバリック ゲーエムベーハー 局所投与方法
WO2018054932A1 (en) 2016-09-22 2018-03-29 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
CN109906085B (zh) 2016-09-23 2024-03-08 诺瓦利克有限责任公司 含有环孢素的眼用组合物
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
SG11202002640YA (en) 2017-09-27 2020-04-29 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
CA3091308A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2019206956A1 (en) 2018-04-27 2019-10-31 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
AU2019345929B2 (en) 2018-09-27 2022-02-03 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
CA3112504A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
MY206642A (en) 2018-10-12 2024-12-30 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
KR20230145053A (ko) 2021-01-12 2023-10-17 듀렉트 코퍼레이션 지속 방출 약물 전달 시스템 및 관련 방법
WO2025056807A1 (en) * 2023-09-15 2025-03-20 Basf Se Stabilized biopolymer composition, their manufacture and use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528516A1 (de) † 1974-07-05 1976-01-22 Sandoz Ag Neue galenische zubereitung
JPS5788115A (en) * 1980-10-06 1982-06-01 Miles Lab Stable non-aqueous solution of tetracycline antibiotic salt
DE3320583A1 (de) † 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPS61189230A (ja) * 1985-02-19 1986-08-22 Nippon Kayaku Co Ltd エトポシド製剤
GB8528959D0 (en) * 1985-11-25 1986-01-02 Leo Pharm Prod Ltd Chemical compounds
DE3636123A1 (de) * 1986-10-23 1988-05-05 Rentschler Arzneimittel Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
JPH0720866B2 (ja) † 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
JP2794022B2 (ja) † 1988-11-11 1998-09-03 三生製薬株式会社 ブナゾシン或いはその塩類含有経皮適用製剤
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
JPH03236317A (ja) † 1989-12-06 1991-10-22 Sansei Seiyaku Kk ドパミン誘導体含有経皮用製剤
US5733572A (en) † 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
EP0520119A1 (de) † 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
WO1993009763A1 (en) † 1991-11-15 1993-05-27 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5314685A (en) † 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
AU6410494A (en) 1993-03-17 1994-10-11 Alza Corporation Device for the transdermal administration of alprazolam
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
ATE149349T1 (de) † 1993-06-25 1997-03-15 Alza Corp Einarbeitung eines poly-n-vinylamids in ein transdermales system
ATE183926T1 (de) 1993-09-29 1999-09-15 Alza Corp Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern
WO1996012495A1 (en) * 1994-10-24 1996-05-02 Nikken Chemicals Co., Ltd Percutaneously administrable preparation
US5736159A (en) † 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
PL184820B1 (pl) * 1995-06-06 2002-12-31 Hoffmann La Roche Dawka jednostkowa kompozycji farmaceutycznej do leczenia chorób wywoływanych przez HIV
US6572879B1 (en) † 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
UA48973C2 (uk) † 1995-06-07 2002-09-16 Орто-Макнейл Фармасьютікалз Інк. Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції
US5906830A (en) † 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5766620A (en) † 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
ES2259746T3 (es) † 1996-07-15 2006-10-16 Alza Corporation Nuevas formulaciones para la administracion transdermica de fluoxetina.
ATE229817T1 (de) † 1996-10-24 2003-01-15 Alza Corp Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
DE19646392A1 (de) † 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
AU739469B2 (en) 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US20020039594A1 (en) † 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
SI9700186B (sl) † 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin

Also Published As

Publication number Publication date
CA2361424A1 (en) 2000-08-10
ES2261190T3 (es) 2006-11-16
EP1666026A2 (en) 2006-06-07
EP1666026B2 (en) 2015-02-25
HK1094528A1 (en) 2007-04-04
CN1339962A (zh) 2002-03-13
KR20080045300A (ko) 2008-05-22
NO20013861D0 (no) 2001-08-08
ZA200106443B (en) 2002-08-06
CN1232244C (zh) 2005-12-21
HUP0200202A2 (hu) 2002-05-29
ES2379471T5 (es) 2015-05-26
DK1666026T3 (da) 2012-04-10
DE60027272D1 (de) 2006-05-24
EP1152749A2 (en) 2001-11-14
DE60027272T2 (de) 2007-01-25
TW200730199A (en) 2007-08-16
CY1119950T1 (el) 2018-12-12
CA2361424C (en) 2009-04-28
DK1666026T4 (da) 2015-05-04
WO2000045790A3 (en) 2000-12-07
PT1152749E (pt) 2006-08-31
EP1152749B1 (en) 2006-04-12
JP2002536315A (ja) 2002-10-29
PT1666026E (pt) 2012-03-15
EP1666026A3 (en) 2007-08-08
TWI292716B (en) 2008-01-21
HUP0200202A3 (en) 2009-08-28
JP4861551B2 (ja) 2012-01-25
WO2000045790A2 (en) 2000-08-10
ATE537811T1 (de) 2012-01-15
HK1041451B (en) 2006-12-01
CO5140096A1 (es) 2002-03-22
KR20010101842A (ko) 2001-11-14
AR029613A1 (es) 2003-07-10
KR100858856B1 (ko) 2008-09-17
AU775904B2 (en) 2004-08-19
ES2379471T3 (es) 2012-04-26
ATE322889T1 (de) 2006-04-15
NZ513441A (en) 2004-01-30
AU3481600A (en) 2000-08-25
IL144755A0 (en) 2002-06-30
EP1666026B1 (en) 2011-12-21
HK1041451A1 (en) 2002-07-12

Similar Documents

Publication Publication Date Title
NO20013861L (no) Stabile, vannfrie, visköse enkeltfaseb¶rere og formuleringer hvor slike benyttes
ATE387492T1 (de) Verfahren und zusammensetzung zur konservierung von adenoviren
UA40578C2 (uk) Сульфоніламінопіримідини і фармацевтичний препарат на їх основі
MY125556A (en) Aqueous formulations of peptide
AP1591A (en) Stable liquid formulations of botulinum toxin
NZ504336A (en) Tetrahydrofuran substituted adenosine A1 receptor agonists, pharmaceuticals thereof, and their use as medicaments
NO306459B1 (no) Amidinderivater med nitrogenoksydsyntetaseaktiviteter, farmasöytisk preparat og anvendelse av amidinderivatene
MXPA05000412A (es) Formulacioneks liquidas con una alta concentracion de hormona de crecimiento humana (hgh) que comprenden glicina.
DK1017413T4 (da) Flydende formulering af interferon-beta
DK1086706T3 (da) Stabiliserede sammensætninger indeholdende nootropiske lægemidler
ATE353636T1 (de) Adhäsive zubereitungen
BR0014384A (pt) Compostos para o tratamento da isquémia
DK1176956T3 (da) Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer
ATE212351T1 (de) Androsten-derivate
IL146312A0 (en) Propanoic acid derivatives that inhibit the binding of integrins to their receptors
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
BR0211060A (pt) Formulação lìquida compreendendo cetuximab e um éster de ácido graxo de polioxietileno sorbitano
NZ240481A (en) Aminosulphonyl urea derivatives and pharmaceutical compositions
BR9914441A (pt) Composição de alta pureza compreendendo (7-alfa, 17-alfa) - 17-hidroxi-7-metil-19-nor-17-pregn- 5(10)-en-20-in-3-ona, processo para preparar as composições de alta pureza, e, unidade de dosagem farmacêutica
ATE305295T1 (de) Vorrichtung zur freigabe von stoffen
ATE367828T1 (de) Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
ATE210978T1 (de) Pharmazeutische zusammensetzung enthaltend uscharin
BR0009821A (pt) Emprego de derivados de maduraftalazina como inibidores de citosinas pró-inflamatórias
NO20001812L (no) Gallesyresalter av metaller med fysiologisk virkning, samt terapeutisk anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application